Division of Women's and Perinatal Pathology, Department of Pathology, Brigham & Women's Hospital/Harvard Medical School, Boston, Massachussetts, United States of America.
PLoS One. 2012;7(11):e50058. doi: 10.1371/journal.pone.0050058. Epub 2012 Nov 26.
Power morcellation has become a common technique for the minimally invasive resection of uterine leiomyomas. This technique is associated with dissemination of cellular material throughout the peritoneum. When morcellated uterine tumors are unexpectedly found to be leiomyosarcomas or tumors with atypical features (atypical leiomyoma, smooth muscle tumor of uncertain malignant potential), there may be significant clinical consequences. This study was undertaken to determine the frequency and clinical consequence of intraperitoneal dissemination of these neoplasms.
METHODOLOGY/PRINCIPAL FINDINGS: From 2005-2010, 1091 instances of uterine morcellation were identified at BWH. Unexpected diagnoses of leiomyoma variants or atypical and malignant smooth muscle tumors occurred in 1.2% of cases using power morcellation for uterine masses clinically presumed to be "fibroids" over this period, including one endometrial stromal sarcoma (ESS), one cellular leiomyoma (CL), six atypical leiomyomas (AL), three smooth muscle tumor of uncertain malignant potential (STUMPs), and one leiomyosarcoma (LMS). The rate of unexpected sarcoma after the laparoscopic morcellation procedure was 0.09%, 9-fold higher than the rate currently quoted to patients during pre-procedure briefing, and this rate may increase over time as diagnostically challenging or under-sampled tumors manifest their biological potential. Furthermore, when examining follow-up laparoscopies, both from in-house and consultation cases, disseminated disease occurred in 64.3% of all tumors (zero of one ESS, one of one CL, zero of one AL, four of four STUMPs, and four of seven LMS). Only disseminated leiomyosarcoma, however, was associated with mortality. Procedures are proposed for pathologic evaluation of morcellation specimens and associated follow-up specimens.
CONCLUSIONS/SIGNIFICANCE: While additional study is warranted, these data suggest uterine morcellation carries a risk of disseminating unexpected malignancy with apparent associated increase in mortality much higher than appreciated currently.
电力分碎术已成为微创切除子宫肌瘤的常用技术。 该技术与细胞物质在整个腹膜内的扩散有关。 当意外发现分碎的子宫肿瘤是平滑肌肉瘤或具有非典型特征的肿瘤(非典型平滑肌瘤,不确定恶性潜能的平滑肌肿瘤)时,可能会产生重大的临床后果。 进行这项研究是为了确定这些肿瘤在腹膜内扩散的频率和临床后果。
方法/主要发现: 在 2005 年至 2010 年期间,在 BWH 确定了 1091 例子宫分碎术。在使用电力分碎术对临床上被认为是“纤维瘤”的子宫肿块进行治疗时,在此期间,1.2%的病例出现了平滑肌瘤变异或非典型和恶性平滑肌肿瘤的意外诊断,包括 1 例子宫内膜间质肉瘤(ESS),1 例细胞平滑肌瘤(CL),6 例非典型平滑肌瘤(AL),3 例平滑肌肿瘤不确定恶性潜能(STUMPs)和 1 例平滑肌肉瘤(LMS)。腹腔镜分碎手术后意外肉瘤的发生率为 0.09%,是术前向患者介绍的目前比率的 9 倍,并且随着时间的推移,诊断具有挑战性或采样不足的肿瘤可能会表现出其生物学潜能,该比率可能会增加。此外,在检查内部和咨询病例的随访腹腔镜检查时,所有肿瘤中有 64.3%(零例 ESS,一例 CL,一例 AL,四例 STUMPs 和七例 LMS)均发生了播散性疾病。只有播散性平滑肌肉瘤与死亡率相关。提出了对分碎标本和相关随访标本进行病理评估的程序。
结论/意义:虽然需要进一步研究,但这些数据表明,子宫分碎术会带来传播意外恶性肿瘤的风险,其死亡率明显高于目前的预期。